Vancomycin

Mayo Clinic Proceedings

Volumn 74, Issue 9, 1999, Pages 928-935

  Wilhelm, Mark P ^a,c   Estes, Lynn ^b  

^a Division of Cardiovascular Diseases and Internal Medicine   (United States)

^b Hospital Pharmacy Services   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ALLERGY; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; CORYNEBACTERIUM; DISEASE ASSOCIATION; DRUG USE; ENDOCARDITIS; GRAM NEGATIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PREVALENCE; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIA; TREATMENT INDICATION; DRUG ADMINISTRATION; REVIEW;

DRUG ADMINISTRATION SCHEDULE; HUMANS; VANCOMYCIN;

EID: 0033194761     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.9.928     Document Type: Conference Paper

References (87)

1. Griffith RS. Vancomycin use-an historical review. J Antimicmb Chemother 1984;14(Suppl D):l-5
2. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989;8:943950
3. Jordan DC, Mallory HOC. Site of action of vancomycin on Staphylococcus aureus. Antimicrob Agents Chemother 1964:489-494
4. Jordan DC, Inniss WE. Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature 1959;184: 1894-1895
5. Watanakunakorn C, Tlsone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillinresistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1982:22:903-905
6. Watanakunakorn C, Bakle C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. Antimicrob Agents Chemother 1973:4:120-124
7. Tedesco F, Markham R, Gurwlth M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978:2:226-228
8. Moellerlng RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984;14(Suppl D):43-52
9. Brown N, Ho DH, Fong KL, Bogerd L, Maksymiuk A, Bolivar R, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983:23:603-609
10. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther DrugMonit 1994;16:513-518
11. Redfleld DC, Underman A, Norman D, Overturf GO. Cerebrospinal fluid penetration of vancomycin in bacterial meningitis. In: Nelson JD, Grassi C, editors. Current Chemotherapy and Infectious Disease. Vol 1. Washington (DC): American Society for Microbiology: 1980. pp 638-641
12. De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 1989;4:635-639
13. BundtzenRW, Gerber AU, Cohn DL, Cralg WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981:3:28-37
14. Hanberger H. Pharmacodynamic effects of antibiotics: studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Scand J Infect Dis Suppl 1992;81:l-52
15. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentrationindependent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996:38:589-597
16. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992:36:1766-1769
17. Dufhill SB, Begg EJ, Chambers ST, Barclay ML. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined-with a dynamic in vitro model. Antimicrob Agents Chemother 1994:38:2480-2482
18. MacGowanAP. Pharmacodynamics, Pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998:20:473477
19. Geracl JE, Hermans PE. Vancomycin. Mayo Clin Proc 1983:58:88-91
20. Baldassarre JS, Ingerman MJ, Nansteel J, Santoro J. Development of Listeria meningitis during vancomycin therapy: a case report [letter]. J Infect Dis 1991:164:221-222
21. Dryden MS, Jones NF, Phillips I. Vancomycin therapy failure in Listeria monocytogenes peritonitis in a patient on continuous ambulatory peritoneal dialysis [letter]. J Infect Dis 1991:164:1239
22. Jaffe HW, Lewis JS, Wiesner PJ. Vancomycin-sensitive Neisseria gonorrhoeas [letter]. J Infect Dis 1981:144:198-199
23. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 1984;14(Suppl D):7-18
24. Rubin LG, Vetlozzi E, Shapiro J, Isenberg HD. Infection with vancomycin-resistant streptococci due to Leuconostoc species [letter]. J Infect Dis 1988:157:216
25. Swenson JM, Facklam RR, Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother 1990;34:543-549
26. Centers for Disease Control and Prevention. Nosocomia enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal WMy Rep 1993:42:597-599
27. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998:26:1196-1199
28. Moellering RC Jr. The specter of glycopeptide resistance: current trends and future considerations. Am J Med 1998;104(Suppl 5A):3S6S
29. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997:41:2016-2018
30. Moellering RC Jr, Cerwinka SL. Early clinical results with quinupristindalfopristin for the therapy of bacteremia due to resistant grampositive bacteria. In: Zinner SH, Young L, Acar J, Neu H, editors. Expanding Indications for the New Macro/ides, Azalides, and Streptogramins. New York: Dekker; 1997. pp 173-176
31. Chien JW, Kucla ML, Salata RA. Use of linezolid, an oxazolidinone, in serious vancomycin resistant enterococcal infections [abstract]. In: Programs and Abstracts of the Infectious Diseases Society of America (IDSA) Annual Meeting; 1998 Nov 12-15; Denver, p 190
32. Sleradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999:340:517-523
33. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, RoblnsonDunn B, et al (Glycopeptlde-lntermedlate Staphylococcus aureus Working Group). Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999:340:493-501
34. Waldvogel FA. New resistance in Staphylococcus aureus [editorial]. N EnglJMed 1999:340:556-557
35. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updates 1998:1:135-150
36. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990:34:1227-1231
37. Evans RC, Holmes CJ. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother 1987:31:889-894
38. Swayne R, Rampling A, Newsom SWB. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J Antimicrob Chemother 1987:19:249-253
39. Bayston R, Hart ÇA, Barnicoat M. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiatry 1987:50:14191423
40. Vlladrich PF, Gudiol F, Linares J, Pallares R, Sabate I, Rufl G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991:35:2467-2472
41. Ahmed A. A critical evaluation of vancomycin for treatment of bacterial meningitis. Pediatr Infect Dis J 1997;16:895-903
42. Dajani AS, Taubert KA, Wilson W, Böiger AF, Bayer A, Ferrlerl P, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Circulation 1997:96:358-366
43. Fekety R, Suva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989:86:1519
44. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981:94:343-346
45. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984:25:433-437
46. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988:32:848-852
47. Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985:5:340-344
48. Matzke GR, Kovarik JM, Rybak MJ, Boike SC. Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 1985:4:311-315
49. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982:22: 391-394
50. Nielsen HE, Hansen HE, Korsager B, Skov PE. Renal excretion of vancomycin in kidney disease. Acta Med Scand 1975;197:261-264
51. Vance-Bryan K, Quay DR, GNIiland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993:37:436-440
52. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 1998;20:261-265
53. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982:21:575-580
54. Andres l, Lopez R, Pou L, Plnol F, Pascual C. Vancomycin monitoring: one or two serum levels? Ther Drug Monit 1997:19:614-619
55. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994;344:1748-1750
56. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. ClinPharm 1987;6:652654
57. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-658
58. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993:27:594-598
59. Rybak MJ, Boike SC. Monitoring vancomycin therapy. Drug Intell Clin Pharm 1986:20:757-761
60. Moellerlng RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? [editorial] [published erratum appears in Clin Infect Dis 1994:19:379]. Clin Infect Dis 1994;18:544-546
61. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994:18:533-543
62. Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995:36:279-282
63. Edwards DJ. Therapeutic drug monitoring of aminoglycosides and vancomycin: guidelines and controversies. JPharmPract 1991:4:211224
64. Mulhern JG, Braden GL, O'Shea MH, Madden RL, Lipkowitz GS, Germain MJ. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995:25:611-615
65. Zimmermann AE, KatonaBG, Plaisance Kl. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995:15:85-91
66. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990:25:679-687
67. Cimino MA, RotsteinC, Slaughter RL, EmrichU. Relationshipof serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83:1091-1097
68. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hématologie malignancies. Clin Pharmacol Ther 1996:60:332-340
69. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994:28:1335-1339
70. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989:33:791796
71. Meyerhoff WL, Maale GE, Yellin W, Roland PS. Audiologic threshold monitoring of patients receiving ototoxic drugs: preliminary report. Ann Otol Rhinol Laryngol 1989;98:950-954
72. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983:23:138-141
73. BannerW Jr, Ray CG. Vancomycin in perspective [editorial]. Am J Dis Child 1984:138:14-16
74. Teresl M, Allison J. Interaction between vancomycin and ticarcillin [letter]. Am J Hosp Pharm 1985:42:2420:2422
75. Barg NL, Supena RB, Fekety R. Persistent staphylococcal bacteremia in an intravenous drug abuser. Antimicrob Agents Chemother 1986:29:209-211
76. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol Adverse Drug Exp 1988;3:376-386
77. Davis RL, Smith AL, Koup JR. The red man's syndrome and slow infusion of vancomycin [letter]. Ann Intern Med 1986:104:285286
78. Sahai J, Healy DP, Garris R, Berry A, Polk RE. Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis 1989:160:876-881
79. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16:235-241
80. Henry K, Steinberg I, Crossley KB. Vancomycin-induced neutropenia during treatment of osteomyelitis in an outpatient. Drug Intell Clin Pharm 1986:20:783-785
81. Koo KB, Bachand RL, Chow AW. Vancomycin-induced neutropenia. Drug Intell Clin Pharm 1986:20:780-782
82. Barna JCJ, Williams DH. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 1984; 38:339-357
83. Williams AH, Grüneberg RN. Teicoplanin revisited. J Antimicrob Chemother 1988:22:397-401
84. Goldstein FW, Coutrot A, Sieffer A. Acar JF. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 1990:34: 899-900
85. Brunei F, Vedel G, Dreyfus F, Vaxelalre JF, Giraud T, Schremmer B, et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 1990:9:145-147
86. Gilbert DN, Wood CA, Kimbrough RC (Infectious Diseases Consortium of Oregon). Failure of treatment with teicoplanin at 6 milligrams/ kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991;35:79-87
87. Jacobus NV, McDermott L, Lonks JR, Boyce JM, Snydman DR. In vitro activity of daptomycin against resistant gram-positive pathogens [abstract]. Program Abstr Intersci Conf Antimicrob Agents Chemother 1998:38:260